BioMarin Pharmaceuticals
BMRN
551 hedge funds and large institutions have $17.4B invested in BioMarin Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 62 funds opening new positions, 205 increasing their positions, 186 reducing their positions, and 81 closing their positions.
92% more call options, than puts
Call options by funds: $238M | Put options by funds: $124M
10% more repeat investments, than reductions
Existing positions increased: 205 | Existing positions reduced: 186
2.47% less ownership
Funds ownership: 98.1% → 95.63% (-2.5%)
5% less funds holding
Funds holding: 579 → 551 (-28)
8% less capital invested
Capital invested by funds: $18.9B → $17.4B (-$1.47B)
23% less first-time investments, than exits
New positions opened: 62 | Existing positions closed: 81
27% less funds holding in top 10
Funds holding in top 10: 15 → 11 (-4)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$246M |
| 2 |
Capital Research Global Investors
Los Angeles,
California
|
+$162M |
| 3 |
State Street
Boston,
Massachusetts
|
+$70.2M |
| 4 |
Primecap Management
Pasadena,
California
|
+$68.7M |
| 5 |
PAMS
Pictet Asset Management (Switzerland)
Geneva 73,
Switzerland
|
+$59.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
-$395M |
| 2 |
Viking Global Investors
Stamford,
Connecticut
|
-$322M |
| 3 |
1832 Asset Management
Toronto,
Ontario, Canada
|
-$101M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$95.2M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$74.2M |
BMRN Hedge Fund Activity: Q1 2023 in Review
551 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in BioMarin Pharmaceuticals (BMRN) for Q1 2023, worth a combined $17.4B — down 7.8% from $18.9B a quarter earlier.
Sellers outnumbered buyers: 81 funds closed out of BMRN and 62 opened new positions — a net loss of 19 holders — while 186 trimmed existing stakes and 205 added.
The largest buyer was Bank of America, adding an estimated $246M. The largest seller was Baker Bros. Advisors, cutting an estimated $395M.
- 551 institutional investors held BioMarin Pharmaceuticals (BMRN) as of Q1 2023, down from 579 in Q4 2022.
- Funds reported $17.4B of BioMarin Pharmaceuticals stock for Q1 2023, down 7.8% quarter-over-quarter.
- 62 funds opened new BioMarin Pharmaceuticals positions in Q1 2023 and 81 closed out, a net change of -19 holders.
- The largest BioMarin Pharmaceuticals buyer in Q1 2023 was Bank of America, an estimated $246M added.
- The largest BioMarin Pharmaceuticals seller in Q1 2023 was Baker Bros. Advisors, an estimated $395M sold.
Based on aggregated 13F filings for Q1 2023.